You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1644 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab,
polatuzumab vedotin,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026
Document
New
Mar 2026

Pages